FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 348:579-580 February 13, 2003 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Grodstein, F. PubMed Citation

In May 2002, the Women's Health Initiative (WHI) trial of daily combined therapy with estrogen and progestin was terminated early. The reason for stopping was an increased risk of breast cancer (and evidence of greater overall risk than benefit) in the hormone-therapy group. Far more surprising, however, was the associated increase in the risk of myocardial infarction. An expectation of coronary benefit had been a major reason for many women's decisions to use postmenopausal hormone therapy.

Earlier reports had failed to show improvement in cardiovascular outcomes in postmenopausal women with known cardiovascular disease who were treated with conjugated equine estrogen . . . [Full Text of this Article]

Source Information

From the Department of Medicine, Brigham and Women's Hospital, Boston (R.G.D.).

Dr. Solomon adjudicates end points for the Women's Health Initiative.

This article has been cited by other articles:

• Figueiredo, J. C., Bernstein, L., Capanu, M., Malone, K. E., Lynch, C. F., Anton-Culver, H., Stovall, M., Bertelsen, L., Haile, R. W., Bernstein, J. L. (2008). Oral Contraceptives, Postmenopausal Hormones, and Risk of Asynchronous Bilateral Breast Cancer: The WECARE Study Group. JCO 26: 1411-1418 [Abstract] [Full Text]  
• Col, N. F. (2006). Decision making at the fringe of evidence: take what you can get.. Arch Intern Med 166: 389-390 [Full Text]  
• Dietel, M., Lewis, M.A., Shapiro, S. (2005). Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20: 2052-2060 [Abstract] [Full Text]  
• Klinge, C. M., Blankenship, K. A., Risinger, K. E., Bhatnagar, S., Noisin, E. L., Sumanasekera, W. K., Zhao, L., Brey, D. M., Keynton, R. S. (2005). Resveratrol and Estradiol Rapidly Activate MAPK Signaling through Estrogen Receptors {alpha} and {beta} in Endothelial Cells. J. Biol. Chem. 280: 7460-7468 [Abstract] [Full Text]  
• Peterson, H. B., Thacker, S. B., Corso, P. S., Marchbanks, P. A., Koplan, J. P. (2004). Hormone Therapy: Making Decisions in the Face of Uncertainty. Arch Intern Med 164: 2308-2312 [Full Text]  
• (2004). Vasomotor Symptoms. Obstet Gynecol 104: 106S-117S [Full Text]  
• Cappuzzo, K. A, Delafuente, J. C (2004). Teriparatide for Severe Osteoporosis. The Annals of Pharmacotherapy 38: 294-302 [Abstract] [Full Text]  
• Hersh, A. L., Stefanick, M. L., Stafford, R. S. (2004). National Use of Postmenopausal Hormone Therapy: Annual Trends and Response to Recent Evidence. JAMA 291: 47-53 [Abstract] [Full Text]  
• Neves-e-Castro, M. (2003). Menopause in crisis post-Women's Health Initiative? A view based on personal clinical experience. Hum Reprod 18: 2512-2518 [Abstract] [Full Text]  
• Wilmer, W. A., Rovin, B. H., Hebert, C. J., Rao, S. V., Kumor, K., Hebert, L. A. (2003). Management of Glomerular Proteinuria: A Commentary. J. Am. Soc. Nephrol. 14: 3217-3232 [Abstract] [Full Text]  
• Ena, G., Rozenberg, S. (2003). Issues to debate on the Women's Health Initiative (WHI) study. Prescription attitudes among Belgian gynaecologists after premature discontinuation of the WHI study. Hum Reprod 18: 2245-2248 [Abstract] [Full Text]  
• Doren, M., Nilsson, J.-A., Johnell, O. (2003). Effects of specific post-menopausal hormone therapies on bone mineral density in post-menopausal women: a meta-analysis. Hum Reprod 18: 1737-1746 [Abstract] [Full Text]